TY  - JOUR
AU  - Sarink, Danja
AU  - Schock, Helena
AU  - Johnson, Theron
AU  - Chang-Claude, Jenny
AU  - Overvad, Kim
AU  - Olsen, Anja
AU  - Tjønneland, Anne
AU  - Arveux, Patrick
AU  - Fournier, Agnès
AU  - Kvaskoff, Marina
AU  - Boeing, Heiner
AU  - Karakatsani, Anna
AU  - Trichopoulou, Antonia
AU  - La Vecchia, Carlo
AU  - Masala, Giovanna
AU  - Agnoli, Claudia
AU  - Panico, Salvatore
AU  - Tumino, Rosario
AU  - Sacerdote, Carlotta
AU  - van Gils, Carla H
AU  - Peeters, Petra H M
AU  - Weiderpass, Elisabete
AU  - Agudo, Antonio
AU  - Rodríguez-Barranco, Miguel
AU  - Huerta, José María
AU  - Ardanaz, Eva
AU  - Gil, Leire
AU  - Kaw, Kay Tee
AU  - Schmidt, Julie A
AU  - Dossus, Laure
AU  - His, Mathilde
AU  - Aune, Dagfinn
AU  - Riboli, Elio
AU  - Kaaks, Rudolf
AU  - Fortner, Renée T
PY  - 2018
DO  - 10.1186/s12885-018-4887-3
UR  - http://hdl.handle.net/10668/13117
T2  - BMC cancer
AB  - Receptor activator of nuclear factor kappa-B (RANK)-signaling is involved in tumor growth and spread in experimental models. Binding of RANK ligand (RANKL) to RANK activates signaling, which is inhibited by osteoprotegerin (OPG). We have previously...
LA  - en
KW  - Breast cancer
KW  - Epidemiology
KW  - Reproductive, hormonal, and related factors
KW  - Serum biomarkers of endogenous exposures
KW  - Adult
KW  - Aged
KW  - Breast Neoplasms
KW  - Case-Control Studies
KW  - Cohort Studies
KW  - Female
KW  - Humans
KW  - Limit of Detection
KW  - Middle Aged
KW  - Osteoprotegerin
KW  - Prognosis
KW  - RANK Ligand
KW  - Risk
TI  - Receptor activator of nuclear factor kB ligand, osteoprotegerin, and risk of death following a breast cancer diagnosis: results from the EPIC cohort.
TY  - research article
VL  - 18
ER  -